| Microorganism |
|
|
|
| Antimicrobial |
 |
|
Reference |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.25 |
4 |
0.06 － 32 |
Levofloxacin (Levaquin, Quixin) |
268 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.25 |
4 |
0.125 － 16 |
Linezolid (PNU-100766, U-100766, Zyvox) |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
>0.25 |
>16 |
≤0.12 － >16 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
0.5 |
0.125 － 1 |
Daptomycin (Cubicin) |
72 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
0.5 |
0.125 － 1 |
Daptomycin (Cubicin) |
207 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
0.5 |
0.5 － 1 |
Tigecycline (GAR-936, Tigacyl) |
16 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
≤0.5 |
≤0.5 |
≤0.5 － >4 |
Clindamycin (Cleocin) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
1 |
0.063 － 2 |
Panduratin A |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
1 |
0.12 － 1 |
Daptomycin (Cubicin) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
1 |
0.125 － >64 |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
178 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
1 |
0.25 － 16 |
Ofloxacin (Floxin) |
117 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
2 |
≤0.01 － 2 |
Oritavancin (LY333328) |
162 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
2 |
0.03 － 4 |
Zosyn |
102 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
4 |
0.25 － 4 |
Teicoplanin (Targocid) |
175 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
>0.5 |
>4 |
≤0.5 － >4 |
Co-trimoxazole (Trimethoprim-sulfamethoxazole, TMP-SMX) |
73 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
16 |
0.5 － 128 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.5 |
32 |
0.5 － 128 |
Tetracycline (Sumycin, Achromycin V, Steclin) |
1464 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
>0.5 |
>128 |
0.125 － >128 |
Erythromycin (E-mycin, Ery-tab, Benzamycin) |
178 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
0.551 |
0.507 |
? － ? |
Ceftobiprole (Zeftera) |
935 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
1 |
0.25 － 2 |
LBM415 (NVP-PDF-713, VIC-10495) |
162 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
1 |
0.5 － 1 |
Daptomycin (Cubicin) |
16 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
1 |
0.5 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
16 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
1 |
0.5 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
175 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
2 |
0.03 － 2 |
Daptomycin + 25 μg/ml Ca++ |
67 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
2 |
≤0.12 － 2 |
Linezolid (PNU-100766, U-100766, Zyvox) |
371 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
2 |
≤0.12 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
371 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
2 |
≤0.12 － 2 |
Vancomycin (Vancocyn, Lyphocin) |
371 |
| Staphylococci (coagulase-negative + methicillin-susceptible) |
1 |
2 |
0.125 － 4 |
LBM415 (NVP-PDF-713, VIC-10495) |
207 |